IN THE CLAIMS:

Please cancel claims 39-63.

Please add the following new claims 64-72:

1-63. (Cancelled)

64. (New) A method of treating the abnormally high acidity in the vagina, comprising:

providing a pharmaceutical formulation essentially consisting of an effective amount of a composition of amino acids, wherein the said composition comprising the following amino acids and/or physiologically acceptable salts thereof: glutamic acid, aspartic acid, isoleucine, phenylalanine, valine, leucine, proline and threonine, a sufficient amount of pharmaceutically acceptable acid or alkali, which results in a pH of the composition from 4.0-8.0, and one or more pharmaceutical carriers;

determining whether the vaginal pH value is less than 4.0; and

if the vaginal pH value is less than 4.0, administering said pharmaceutical composition vaginally.

65. (New) A method for treating vaginitis in which the acidity level of the vagina is abnormally high comprising:

providing a pharmaceutical formulation essentially consisting of an effective amount of a composition of amino acids, wherein the said composition comprising the following

amino acids and/or physiologically acceptable salts thereof: glutamic acid, aspartic acid, isoleucine, phenylalanine, valine, leucine, proline and threonine, a sufficient amount of pharmaceutically acceptable acid or alkali, which results in a pH of the composition from 4.0-8.0, and one or more pharmaceutical carriers;

determining whether the vaginal pH value is less than 4.0; and

if the vaginal pH value is less than 4.0, administering said pharmaceutical composition vaginally.

66. (New) A method for treating fungal vaginitis in which the acidity level of the vagina is abnormally high comprising:

providing a pharmaceutical formulation essentially consisting of an effective amount of a composition of amino acids, wherein the said composition comprising the following amino acids and/or physiologically acceptable salts thereof: glutamic acid, aspartic acid, isoleucine, phenylalanine, valine, leucine, proline and threonine, a sufficient amount of pharmaceutically acceptable acid or alkali, which results in a pH of the composition from 4.0-8.0, and one or more pharmaceutical carriers;

determining whether the vaginal pH value is less than 4.0; and

if the vaginal pH value is less than 4.0, administering said pharmaceutical composition vaginally.

67. (New) The method according to Claims 64, 65 or 66 wherein the said composition of amino acids in said pharmaceutical formulation further comprises one or more of the following amino acids and/or physiologically acceptable salts thereof: methionine, tyrosine, cysteine, alanine, glycine, serine, lysine, glutamine, asparagine, arginine, tryptophane and histidine.

68. (New) The method according to Claims 64, 65, or 66 further comprising providing said pharmaceutical formulation in the form of viscous gels, lotion, tablets, effervescent tablets, suppositories, emulsion, ointments or micro-capsules.

69. (New) The method according to Claim 68, further comprising providing said pharmaceutical formulation in the form of a viscous gel, lotion or emulsion, wherein the total content of amino acids and/or the physiologically acceptable salts thereof is in the range of 30-350mmol/L.

70. (New) The method according to Claim 69, wherein the total content of amino acids and/or the physiologically acceptable salts thereof is in the range of 80-200mmol/L.

71. (New) The method according to Claim 64, wherein the said physiologically acceptable salts of amino acids is the sodium salt, potassium salt, calcium salt or magnesium salt of amino acids.

72. (New) The method according to Claim 71, wherein the said physiologically acceptable salt of amino acid is the sodium salt of amino acid.